Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Operating Leases (2019 - 2025)

Amicus Therapeutics filings provide 7 years of Operating Leases readings, the most recent being $49.7 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 10.26% to $49.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.7 million, a 10.26% increase, with the full-year FY2025 number at $49.7 million, up 10.26% from a year prior.
  • Operating Leases hit $49.7 million in Q4 2025 for Amicus Therapeutics, up from $42.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $57.2 million in Q4 2023 to a low of $42.2 million in Q3 2025.
  • Median Operating Leases over the past 5 years was $48.8 million (2024), compared with a mean of $48.4 million.
  • Biggest five-year swings in Operating Leases: grew 19.58% in 2022 and later decreased 21.19% in 2024.
  • Amicus Therapeutics' Operating Leases stood at $50.8 million in 2021, then rose by 1.59% to $51.6 million in 2022, then increased by 10.9% to $57.2 million in 2023, then decreased by 21.19% to $45.1 million in 2024, then grew by 10.26% to $49.7 million in 2025.
  • The last three reported values for Operating Leases were $49.7 million (Q4 2025), $42.2 million (Q3 2025), and $43.4 million (Q2 2025) per Business Quant data.